

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Oventus Medical Limited</b>
<b>ABN</b>	<b>12 608 393 282</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Melvyn John Bridges
<b>Date of last notice</b>	8 March 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Mel Bridges & Lucille Bridges atf The Bridges Super Fund
<b>Date of change</b>	9 August 2017

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p>Direct: 44,000 Ordinary Shares; &amp; 200,732 Options exercisable at \$0.578 ea; expiring 23 February 2021          Indirect – interests held by Parma Corporation Pty Ltd 696,300 Ordinary Shares          Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 102,729 Ordinary Shares          Indirect – interests held by Melvyn Bridges &amp; Lucille Bridges as trustees for the Bridges Super Fund 128,058 Ordinary Shares          Indirect – Lucille Bridges (spouse) 91,837 Ordinary Shares</p>
<p><b>Class</b></p>	<p>Ordinary Shares</p>
<p><b>Number acquired</b></p>	<p>Direct – 27,778 Ordinary Shares          Indirect – interests held by Parma Corporation Pty Ltd 444,444 Ordinary Shares          Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 41,666 Ordinary Shares          Indirect – interests held by Melvyn Bridges &amp; Lucille Bridges as trustees for the Bridges Super Fund 138,889 Ordinary Shares          Indirect – Lucille Bridges (spouse) Nil</p>
<p><b>Number disposed</b></p>	<p>Nil</p>
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Direct – \$10,000          Indirect – interests held by Parma Corporation Pty Ltd \$160,000          Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust \$15,000          Indirect – interests held by Melvyn Bridges &amp; Lucille Bridges as trustees for the Bridges Super Fund \$50,000</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p>Direct: 71,778 Ordinary Shares; &amp; 200,732 Options exercisable at \$0.578 ea; expiring 23 February 2021</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,140,744 Ordinary Shares</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 144,395 Ordinary Shares</p> <p>Indirect – interests held by Melvyn Bridges &amp; Lucille Bridges as trustees for the Bridges Super Fund 266,947 Ordinary Shares</p> <p>Indirect – Lucille Bridges (spouse) 91,837 Ordinary Shares</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Purchased under the Second Tranche Placement approved by Shareholders on 3 August 2017

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed</p>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Not in a closed period
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.